Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Director Acquires $99,125.00 in Stock

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Get Free Report) Director Frank Karbe acquired 12,500 shares of the stock in a transaction on Friday, December 13th. The shares were acquired at an average cost of $7.93 per share, for a total transaction of $99,125.00. Following the completion of the transaction, the director now directly owns 57,000 shares in the company, valued at $452,010. The trade was a 28.09 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Phathom Pharmaceuticals Price Performance

Shares of PHAT stock traded up $0.25 during mid-day trading on Monday, hitting $8.14. The stock had a trading volume of 1,024,022 shares, compared to its average volume of 915,794. Phathom Pharmaceuticals, Inc. has a fifty-two week low of $6.07 and a fifty-two week high of $19.71. The firm has a market cap of $556.61 million, a PE ratio of -1.43 and a beta of 0.56. The company's 50-day simple moving average is $12.74 and its 200-day simple moving average is $13.17.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on PHAT shares. HC Wainwright reissued a "buy" rating and set a $28.00 price objective on shares of Phathom Pharmaceuticals in a research report on Thursday. Needham & Company LLC reissued a "buy" rating and set a $28.00 price objective on shares of Phathom Pharmaceuticals in a research report on Wednesday, December 11th.

Institutional Trading of Phathom Pharmaceuticals

Several hedge funds have recently made changes to their positions in PHAT. Price T Rowe Associates Inc. MD lifted its position in shares of Phathom Pharmaceuticals by 12.5% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 19,573 shares of the company's stock valued at $208,000 after acquiring an additional 2,172 shares during the period. Bank of New York Mellon Corp increased its stake in Phathom Pharmaceuticals by 20.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 114,721 shares of the company's stock valued at $1,182,000 after purchasing an additional 19,500 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Phathom Pharmaceuticals by 42.2% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,071 shares of the company's stock worth $104,000 after purchasing an additional 2,987 shares during the last quarter. Rhumbline Advisers boosted its position in Phathom Pharmaceuticals by 17.1% during the second quarter. Rhumbline Advisers now owns 55,178 shares of the company's stock worth $568,000 after purchasing an additional 8,075 shares in the last quarter. Finally, Marshall Wace LLP acquired a new stake in Phathom Pharmaceuticals in the second quarter valued at $1,161,000. Institutional investors and hedge funds own 99.01% of the company's stock.

Phathom Pharmaceuticals Company Profile

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.